INIFY LABORATORIES AB (WY60) - Total Liabilities
Based on the latest financial reports, INIFY LABORATORIES AB (WY60) has total liabilities worth €23.00 Million EUR (≈ $26.89 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See WY60 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
INIFY LABORATORIES AB - Total Liabilities Trend (2021–2025)
This chart illustrates how INIFY LABORATORIES AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see INIFY LABORATORIES AB assets under control.
INIFY LABORATORIES AB Competitors by Total Liabilities
The table below lists competitors of INIFY LABORATORIES AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ant Precision Industry Co Ltd
TWO:3646
|
Taiwan | NT$397.76 Million |
|
Rocketboots Ltd
AU:ROC
|
Australia | AU$2.01 Million |
|
Stria Lithium Inc
V:SRA
|
Canada | CA$111.99K |
|
Exxaro Tiles Limited
NSE:EXXARO
|
India | Rs2.08 Billion |
|
Katana Capital Ltd
AU:KAT
|
Australia | AU$4.82 Million |
|
Qingdao Hengshun Zhongsheng
SHE:300208
|
China | CN¥2.41 Billion |
|
Petrolia SE
F:0PE
|
Germany | €27.62 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down INIFY LABORATORIES AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See WY60 equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how INIFY LABORATORIES AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for INIFY LABORATORIES AB (2021–2025)
The table below shows the annual total liabilities of INIFY LABORATORIES AB from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €34.02 Million ≈ $39.77 Million |
+258.09% |
| 2024-12-31 | €9.50 Million ≈ $11.11 Million |
+19.42% |
| 2023-12-31 | €7.95 Million ≈ $9.30 Million |
-42.18% |
| 2022-12-31 | €13.76 Million ≈ $16.08 Million |
-- |
| 2021-12-31 | €0.00 ≈ $0.00 |
-- |
About INIFY LABORATORIES AB
INIFY Laboratories AB provides cancer diagnostics services in Sweden. It offers prostate cancer diagnostics services. The company was incorporated in 2021 and is based in Stockholm, Sweden.